Skip to main content
. 2021 Nov 1;57:103363. doi: 10.1016/j.msard.2021.103363

Table 3.

DMTs used by the participants.

Drug name Number (%) Drug name Number (%)
No drug 26 (3.5) Natalizumab 28 (3.7)
IFN beta-1a (IM) 96 (12.7) Rituximab 229 (30.4)
IFN beta-1a (SC) 39 (5.2) Ocrelizumab 21 (2.8)
IFN beta-1b 17 (2.3) Cyclophosphamide 1 (0.1)
Glatiramer acetate 46 (6.1) Mitoxantrone 2 (0.3)
Teriflunomide 16 (2.1) Azathioprine 3 (0.4)
Dimethyl fumarate 99 (13.1) Mycophenolate mofetil 1 (0.1)
Fingolimod 97 (12.9) Missing 31 (4.3)